Translumbar Infusion of N-Butyl Cyanoacrylate for the Treatment of Type II Endoleaks

• Published in: Journal of vascular and interventional radiology Vol. 29; no. 6; pp. 826 - 832
• Main Authors: Lagios, Kostantinos, Karaolanis, Georgios, Bazinas, Theodoros, Perdikides, Theodossios, Bountouris, Ioannis
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-06-2018
• Subjects: EVAR; NBCA
• ISSN: 1051-0443; 1535-7732
• DOI: 10.1016/j.jvir.2018.01.788

To evaluate long-term efficacy of translumbar embolization of type II endoleaks exclusively supplied by the lumbar arteries in patients with growing abdominal aortic aneurysm sacs using N-butyl cyanoacrylate (NBCA) instilled via percutaneous needle access.
The study included 25 patients who developed type II endoleak after endovascular aneurysm repair. Inclusion criteria for intervention were defined as sac expansion > 5 mm detected with CT angiography at 6-month follow-up or later. Translumbar infusion of NBCA directly into the patent portion of the aneurysm sac was performed in all cases. Duplex US was performed the day after the intervention, and CT angiography was performed within the first month. Subsequently, duplex US was performed at 3, 6, and 9 months, and CT angiography or CT was performed at 12 months and annually thereafter.
Translumbar embolization was achieved in all 25 patients. The endoleak resolved in 22 patients (88%) on duplex US performed 1 day after the embolization procedure. Three patients with persistent endoleak (12%) required repeat embolization. Two complications were detected and were managed conservatively.
This study demonstrates the safety and efficacy of NBCA injection for treatment of type II endoleaks. This technique provides another option for the management of type II endoleaks.